Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Sleep disturbances in patients with multiple sclerosis.
Central Nervous System Expression and PET Imaging of the Translocator Protein in Relapsing-Remitting Experimental Autoimmune Encephalomyelitis.
Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
People with Multiple Sclerosis use many fall prevention strategies but still fall frequently.
Intractable Vomiting Antecedent to Optic Neuritis: An Early Clinical Clue to Neuromyelitis Optica.
Three Distinct Motifs within the C-terminus of ASIC1a Regulate its Surface Trafficking.
The clinical relevance of force platform measures in multiple sclerosis: a review.
Fitness and cognitive processing speed in persons with multiple sclerosis: A cross-sectional investigation.
Impact of Armodafinil on Cognition in Multiple Sclerosis: A Randomized, Double-blind Crossover Pilot Study.
Alexithymia in Neurological Disease: A Review.
Progressive multifocal leukoencephalopathy: Dot-shaped inclusions and virus-host interactions.
Mechanisms of cell-cell interaction in oligodendrogenesis and remyelination after stroke.
The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing-remitting multiple sclerosis.
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.
CNS-wide Sexually Dimorphic Induction of the Major Histocompatibility Complex 1 Pathway With Aging.
Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-γ and alpha B-crystallin.
Claudin Proteins And Neuronal Function.
Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.
[Quality of life in multiple sclerosis--association with clinical features, fatigue and depressive syndrome].
[Natalizumab as induction therapy in multiple sclerosis.]
Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
Distinct serum apolipoprotein A-I levels in neuromyelitis optica and acute transverse myelitis.
Relapsing optic neuritis: a multicentre study of 62 patients.
Promoting return of function in multiple sclerosis: An integrated approach.
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.

Pages